Health Based Guidance for Air
Site Assessment and Consultation Unit
Environmental Health Division
651-201-4899

Web Publication Date: May 2024

Air Toxicological Summary for: FORMALDEHYDE

CAS: **50-00-0**

Synonyms: Formic aldehyde, methyl aldehyde, methylene oxide, oxymethylene, formalin, formol, methanal, oxomethane

Air Exposure Durations:

Acute - dosing duration 24-hours or less

Short-term - repeated dosing for more than 24-hours, up to approximately 30 days

Subchronic - repeated dosing for more than 30 days, up to approximately 8 years (10 percent of a lifespan in humans; more than 30 days up to approximately 90 days in typical laboratory rodent species)

Chronic - repeated dosing for more than approximately 8 years (10 percent of a life span in humans; more than approximately 90 days in typical laboratory rodent species)

Acute Non-Cancer Health Based Value ($nHBV_{Acute}$) = 50 µg/m³

$$= \frac{\text{(Point of Departure (POD), mg/m}^3\text{)}}{\text{(Uncertainty Factors (UF))}}$$

$$= \frac{\text{(0.53 mg/m}^3\text{)}}{\text{(10)}}$$

$$= 0.053 \text{ mg/m}^3 \text{ rounded to } 50 \text{ µg/m}^3$$

Reference Concentration:	HEC/Total UF = 0.53/10 = 0.053 mg/m³
Source of toxicity value:	MDH 2019; Kulle et al. 1987 (human study)
POD and Critical Effect:	$BMDL_{10}$ = 0.53 mg/m³; mild/moderate eye irritation in healthy adults
Human Equivalent Concentration (HEC):	No DAF needed, human study
Total uncertainty factor (UF):	10
Uncertainty factor allocation:	$UF_{H\text{-}d}$ was set at 10 due to a lack of sensitive subjects in the critical study population; $UF_{H\text{-}k}$ was set at 1 because critical effect is point of entry sensory irritation

Short-term Non-Cancer Health Based Value ($nHBV_{ST}$) = 7 µg/m³

$$= \frac{(POD\ mg/m^3)}{(UF)}$$

$$= \frac{(0.021\ mg/m^3)}{(3)}$$

$$= 0.007\ mg/m^3 = 7\ \mu g/m^3$$

Reference Concentration:	HEC/Total UF = 0.021mg/m³/3 = 0.007 mg/m³
Source of toxicity value:	Krzyzanowski et al. 1990; aci EPA 2022 (human study)
POD and Critical Effect:	$BMCL_{10}$ = 0.021 mg/m³; pulmonary function - decline in peak expiratory flow rate (PEFR)
Human Equivalent Concentration:	$BMCL_{10}$ = 0.021 mg/m³
Total uncertainty factor:	3
Uncertainty factor allocation:	UF_{H-d} = 3 as asthmatic children were included in study

Subchronic Non-Cancer Health Based Value ($nHBV_{Subchronic}$) = 7 µg/m³ (set to short-term HBV)

$$= \frac{(POD\ mg/m^3)}{(UF)}$$

$$= \frac{(0.09\ mg/m^3)}{(10)}$$

$$= 0.009\ mg/m^3 = 9\ \mu g/m^3$$

Reference Concentration:	HEC/Total UF = 0.09/10 = 0.009 mg/m³
Source of toxicity value:	Wilhelmsson and Holmstrom 1992; aci in Cal OEHHA 2008 (human study)
POD and Critical Effect:	NOAEL = 0.09 mg/m³; eye irritation, nasal obstruction and discomfort, and lower airway discomfort
Human Equivalent Concentration (HEC):	No DAF needed, human study
Total uncertainty factor (UF):	10
Uncertainty factor allocation:	UF_{H-d} was set at 10 due to a lack of sensitive subjects in the critical study population; UF_{H-k} was set at 1 because critical effect is point of entry sensory irritation

Chronic Non-Cancer Health Based Value ($nHBV_{Chronic}$) = 7 µg/m³ (set to short-term HBV)

$$= \frac{(POD\ mg/m^3)}{(UF)}$$

$$= \frac{(0.09\ mg/m^3)}{(10)}$$

= 0.009 mg/m^3 = 9 µg/m^3

Reference Concentration:	HEC/Total UF = 0.09/10 = 0.009 mg/m^3
Source of toxicity value:	Wilhelmsson and Holmstrom 1992; aci in Cal OEHHA 2008 (human study)
POD and Critical Effect:	NOAEL = 0.09 mg/m^3; eye irritation, nasal obstruction and discomfort, and lower airway discomfort
Human Equivalent Concentration (HEC):	No DAF needed, human study
Total uncertainty factor (UF):	10
Uncertainty factor allocation:	UF_{H-d} was set at 10 due to a lack of sensitive subjects in the critical study population; UF_{H-k} was set at 1 because critical effect is point of entry sensory irritation

Cancer Health Based Value/Risk Assessment Advice = Not Derived**

**Based on current carcinogenic mode of action information, MDH has determined formaldehyde to be a nonlinear carcinogen. Use of an inhalation unit risk, based on a linear approach, to evaluate ambient levels of formaldehyde is considered inappropriate and not recommended by MDH. MDH's noncancer short-term HBV (7 µg/m^3 each) based on pulmonary effects (decreased PEFR), is a more sensitive endpoint than the cancer precursor effects of cytotoxicity and regenerative cellular proliferation. Therefore, the noncancer short-term HBV is considered protective of cancer effects.

Volatile: Yes (average Henry's Law = $3.37e^{-7}$ atm-m^3/mol; EPA ChemDashboard, as of April 2024)

Summary of Guidance Value History:

MDH first derived a cancer HRV of 0.8 µg/m^3, based on USEPA IRIS (1989) in 1995. This cancer value was revised to 2.0 µg/m^3 in 2006, based on CalEPA 1992. In 2002 MDH also derived a noncancer acute HRV of 94 µg/m^3 based on CalEPA 1992. In 2019 MDH re-evaluated formaldehyde and derived acute, subchronic and chronic nHBVs of 50, 9, and 9 µg/m^3, respectively. The 2019 evaluation determined that formaldehyde was a nonlinear carcinogen and the subchronic and chronic nHBVs of 9 µg/m^3 are protective of cancer effects.

Summary of toxicity testing for health effects identified in the Health Standards Statute (144.0751):
Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. MDH has considered the following information in developing health protective guidance.

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity	Respiratory
Tested for specific effect?	Yes	Yes	Yes	Yes	Yes	Yes
Effects observed?	Yes[1]	Yes[2]	Yes[3]	Yes[4]	Yes[5]	Yes[6]

Comments on extent of testing or effects:

[1] EPA IRIS Draft 2010 concluded that an endocrine-disrupting MOA is supported by some of the reproductive and developmental epidemiology and toxicology studies. Decreases in fetal body weight (6,000 – 49,000 µg/m^3), delayed ossifications, and delayed eruption of incisors noted in rats after gestational exposure to formaldehyde are consistent with developmental delays (concentrations ranging from 500 – 49,000 µg/m^3). Studies that directly tested for changes in hormones after formaldehyde exposure observed ovarian weight and serum LH and FSH increases after inhaled formaldehyde in adult female rats (490 – 1500 µg/m^3). In human studies, an endocrine MOA could also explain delayed time to pregnancy and increased incidence of spontaneous abortion (at a mean formaldehyde concentration of ~270 µg/m^3), consistent with some study findings from the toxicology literature. Short-term rat exposures to 860 or 3000 µg/m^3 formaldehyde increased basal corticosterone levels in the serum and exposure of female mice to 100, ~500, and 2500 µg/m^3 formaldehyde weeks produced increases in the number of corticotrophin-releasing hormone-immunoreactive neurons in the hypothalamus. Similarly, increases in adrenocorticotropin hormone-immunoreactive cells in the anterior pituitary gland were observed in mice exposed to formaldehyde at approximately 100, 500, and 2500 µg/m^3.

[2] EPA IRIS Draft 2010 reported studies in four specific areas related to immunotoxicity after exposure to formaldehyde: increased upper respiratory tract infections, systemic immune dysfunction, sensitization and atopy, and production of formaldehyde-protein complexes (ranging from 390 to 25,000 μg/m^3. Some studies also evaluated immune system effects by investigating the role of reactive oxygen species from respiratory burst associated with immune cells and by assessing chromosomal damage in immune cells (range of 390 to 25,000 μg/m^3). The NAS 2011 Review provided the following recommendations: the systemic nature of the immune system and the interplay between the innate and adaptive arms of the immune system provide a plausible potential target of formaldehyde, despite its limited distribution beyond the point of entry. The committee agreed with EPA's decision not to calculate a candidate RfC for immunotoxicity.

[3] ATSDR 2010 addendum reported effects of maternal exposure to inhaled formaldehyde on embryonic and fetal toxicity in Sprague-Dawley rats. Groups of 25 dams were exposed to 0, 6,000, 12,000, 25,000, or 49,000 μg/m^3 formaldehyde in inhalation chambers on gestational days 6-20. Fetal body weights of male offspring from dams exposed to 25,000 μg/m^3 formaldehyde were 5% lower than controls ($p<0.05$). Furthermore, fetal body weights of male and female offspring from dams exposed to 49,000 μg/m^3 formaldehyde ($p<0.01$) were about 21% lower than those offspring of controls. Therefore, maternal exposure to formaldehyde at 49,000 μg/m^3 for 6 hours/day during gestational days 6– 20 was not teratogenic nor embryotoxic, but exposure at 25,000 μg/m^3 was slightly fetotoxic, as indicated by lower fetal body weights. Another study examined embryotoxics effect and fetal and juvenile offspring development from mongrel female white rat dams exposed to 0 or 490 μg/m^3 formaldehyde for 4 hours/day on gestational days 1-19. The results showed that prenatal exposure to formaldehyde does not affect the embryonic mortality and does not decrease the crown-tail (craniocaudal) lengths or the weights of embryos. However, examination of internal organs of the prenatal formaldehyde-exposed group revealed decreased fetal hyoid ossification and increased incidence of total anomalies, with absence of testes as the predominant anomaly.

The NAS committee disagreed with EPA's overall conclusion regarding the totality of the epidemiologic evidence related to the reproductive and developmental effects of formaldehyde. Specifically, the draft IRIS assessment stated that "epidemiologic studies suggest a convincing relationship between occupational exposure to formaldehyde and adverse reproductive outcomes in women" (EPA 2010, p. 4-85). The committee, after assessing the literature, found a suggestive pattern of association among a small number of studies rather than a convincing relationship. The committee's assessment was based on the overall pattern of positive association among most of the studies, but the generally limited exposure assessment and concern about other biases lead to the more appropriate descriptor of suggestive rather than convincing.

[4] ATSDR 2010 addendum, several comprehensive reviews concluded that formaldehyde does not produce significant reproductive and developmental toxicity. In a review of available reproductive and developmental toxicity data for humans and laboratory animals, the World Health Organization concluded, "There is no convincing evidence that formaldehyde is a teratogen in either animals or human beings. Formaldehyde has not produced any adverse effects on reproduction in test animals or human beings". EPA IRIS Draft 2010 stated that several epidemiologic studies report a relationship between occupational exposure to formaldehyde and increases in risk of spontaneous abortion following maternal occupational formaldehyde exposure (at a mean formaldehyde concentration of ~270 μg/m^3). However, other studies

found no association between occupational formaldehyde exposure and spontaneous abortion. Paternal occupational exposure to formaldehyde was not related to spontaneous abortion.

[5] EPA IRIS Draft 2010 stated one study reported elevations in the mRNA for NMDA receptor subunits in brain homogenates following exposure to 2,900 μg/m^3. Another study reported a significant increase in NMDA receptor subunit transcripts, along with other neuropeptide genes, in nasal tissue of rats instilled into nostril with 400 mM formaldehyde (Described in EPA IRIS Draft 2010 Section 4.2.1.2.2.1). Together, these changes may be related to formaldehyde-induced sensory irritation and, perhaps, changes throughout the brain. In general, behavioral effects in animals and humans appear to occur at similar exposure levels. Animal studies demonstrated LOAELs as low as 123 μg/m^3 following acute or repeated exposures; human controlled exposure studies have found effects in that same range, with LOAELs of approximately 370 μg/m^3 following acute exposures. In a controlled exposure study, it was reported that, when workers with chronic formaldehyde exposure were challenged with an acute formaldehyde exposure, they exhibited poorer performance on some neurocognitive tests compared with workers without chronic exposure undergoing the same acute challenge conditions. Per NAS 2011 Formaldehyde review, the committee found that EPA overstated the evidence in concluding that formaldehyde is neurotoxic; the human data are insufficient, and the candidate animal studies deviate substantially from neurotoxicity-testing guidelines and common practice… There was concern that the selected studies were not sufficiently robust in design to be considered "well executed" for the purpose of neurotoxicity hazard identification.

[6] EPA IRIS Draft 2010 stated exposure to formaldehyde in early life can cause damage to the lungs and permanently influence airway function, resulting in increased vulnerability to toxicants later in life. Thus, young children may demonstrate increased susceptibility to formaldehyde-related health effects. One study reported an association between physician-diagnosed asthma and chronic bronchitis in children who lived in homes with formaldehyde levels that were higher than 74 μg/m^3, after controlling for socioeconomic status and ethnicity. Another study reported a statistically significant increased risk of asthma with increased residential concentrations (30 μg/m^3 - lower limit of NOAEL range) of formaldehyde. Another study reported an increased association between bedroom concentration (ranging from 16 – 139 μg/m^3) of formaldehyde and increased risk of atopy in children. These studies suggested that formaldehyde exposure may exacerbate responses in sensitive airways, particularly in children. Animal studies have shown evidence and confirmed that the upper respiratory tract is a critical target for inhaled formaldehyde and that exposure-response relationships for upper respiratory tract irritation and epithelial damage exist in several species. Acute animal studies have also shown that inhaled formaldehyde at certain exposure concentrations damages epithelial tissue in specific regions of the upper respiratory tract in rats, mice, and monkeys.

Resources Consulted During Review:

Agency for Toxic Substances and Disease Registry (ATSDR). 1999. Toxicological Profile for Formaldehyde.

Agency for Toxic Substances and Disease Registry (ATSDR). 2010. Addendum to the Toxicological Profile for Formaldehyde.

California OEHHA. December 2008 (Updated July 2014). Appendix D. Individual Acute, 8-Hour, and Chronic Reference Exposure Level Summaries. https://oehha.ca.gov/media/downloads/crnr/appendixd1final.pdf

Krzyzanowski, M; Quackenboss, JJ; Lebowitz, MD. 1990. Chronic respiratory effects of indoor formaldehyde exposure. Environ Res 52: 117-125. http://dx.doi.org/10.1016/S0013-9351(05)80247-6

Kulle, TJ; Sauder, LR; Hebel, JR; Green, DJ; Chatham, MD. 1987. Formaldehyde dose-response in healthy nonsmokers. J Air Pollut Control Assoc 37: 919-924.

National Academy of Sciences. 2011. Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde. The National Academies Press. Washington DC. https://www.nap.edu/catalog/13142/review-of-the-environmental-protection-agencys-draft-iris-assessment-of-formaldehyde

US EPA IRIS. 2010. Toxicological Review of Formaldehyde – Inhalation Assessment DRAFT. EPA/635/R-10/002A

US EPA IRIS. 2022. Toxicological Review of Formaldehyde – Inhalation External Review DRAFT. EPA/635/R-22/039a.

Wilhelmsson, B; Holmström, M. 1992. Possible mechanisms of formaldehyde-induced discomfort in the upper airways. Scand J Work Environ Health 18:403–407.